U.S. Markets closed

Cytokinetics, Incorporated (CYTK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
40.73+1.46 (+3.72%)
At close: 4:00PM EST

Cytokinetics, Incorporated

280 East Grand Avenue
South San Francisco, CA 94080
United States
650 624 3000

Full Time Employees184

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert I. BlumCEO, Pres & Director1.02M1.41M1964
Mr. Ching W. JawSr. VP & CFO605.85k985.9k1963
Mr. David W. CraggChief HR & Admin. Officer541.12k192.99k1956
Mr. Mark A. SchlossbergSr. VP of Legal, Gen. Counsel & Sec.625.06k340.13k1961
Dr. Fady Ibraham MalikExec. VP of R&D691.06kN/A1964
Dr. James A. SpudichCo-Founder & Member of Scientific Advisory BoardN/AN/A1942
Mr. Jeff LotzVP of Sales & OperationsN/AN/AN/A
Mr. Robert WongVP & Chief Accounting OfficerN/AN/A1967
Ms. Diane WeiserSr. VP of Corp. Communications & Investor RelationsN/AN/AN/A
Ms. Bonnie A. CharpentierSr. VP of Regulatory Affairs & ComplianceN/AN/A1952
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Corporate Governance

Cytokinetics, Incorporated’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 9; Board: 4; Shareholder Rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.